do we have reliable biomarkers to guide use of immunotherapy agents?
Published 6 years ago • 450 plays • Length 24:22Download video MP4
Download video MP3
Similar videos
-
19:00
biomarkers predicting clinical activity of immunocheckpoints
-
31:15
keynote lecture: managing side effects of io agents
-
46:29
biomarkers in cancer immunotherapy: what patients need to know
-
1:29
the challenges of using biomarkers for immunotherapy
-
24:18
immunotherapy biomarkers and patient selection
-
42:53
biomarkers in cancer immunotherapy: how much do they matter?
-
12:01
debate: is circulating tumor dna ready to guide adjuvant therapy in colon cancer? - yes
-
18:46
integrating immunotherapy into current treatment algorithms for gi cancers
-
21:20
overview of immunotherapy in gi cancers
-
6:47
new biomarkers for response to immunotherapy
-
14:08
challenging clinical cases: what factors should guide your choice of therapy
-
22:06
the basics of immunotherapy in non-small cell lung cancer (nsclc)
-
7:32
the promise of immunotherapy in bladder cancer
-
21:38
unique toxicities of immunotherapy
-
1:02:45
biomarkers in breast cancer: current practice, opportunities and unmet needs
-
20:15
response criteria and kinetics with immunocheckpoint inhibitors
-
3:10
bcma: a new biomarker for multiple myeloma
-
15:15
first line therapies for ulcerative colitis and crohn's disease
-
29:45
keynote lecture 4: the braf pathway in crc?